AgingResearch.NewsJoin free

Principia Biopharma

Part of Sanofi

CompanyUnited StatesFounded 2008

Wikidata

Principia Biopharma develops one asset, approved (rilzabrutinib in immune thrombocytopenia). Mostly small molecule acting on BTK; based in the United States, founded in 2008.

1
Asset
Furthest stage
Approved
Raised
$143M
1
Trial
5
Signals

Pipeline

1

  • rilzabrutinib

    Inhibits Bruton tyrosine kinase to reduce immune-mediated platelet destruction.

    Approved, Small molecule, BTK, immune thrombocytopenia, persistent and chronic immune thrombocytopenia

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials1
  • Funding rounds and grants5
  • Signals7
  • Similar companies6

Intelligence